0KF3 Profitability Analysis: Past Growth, Margins, Return on Capital, Free Cash Flow, and more - Palatin Technologies Inc - Alpha Spread
P

Palatin Technologies Inc
LSE:0KF3

Watchlist Manager
Palatin Technologies Inc
LSE:0KF3
Watchlist
Price: 1.46 USD -0.75% Market Closed
Market Cap: 40.1B USD
Have any thoughts about
Palatin Technologies Inc?
Write Note

Profitability Summary

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
Palatin Technologies Inc

Revenue
5.9m USD
Cost of Revenue
-197.6k USD
Gross Profit
5.7m USD
Operating Expenses
-38.5m USD
Operating Income
-32.8m USD
Other Expenses
-106.2k USD
Net Income
-32.9m USD

Margins Comparison
Palatin Technologies Inc Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
US
Palatin Technologies Inc
LSE:0KF3
40.1B USD
97%
-555%
-557%
US
Abbvie Inc
NYSE:ABBV
344.8B USD
67%
29%
10%
US
Amgen Inc
NASDAQ:AMGN
180B USD
63%
20%
10%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
128.6B USD
87%
31%
32%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
126B USD
86%
41%
-5%
US
Epizyme Inc
F:EPE
94.1B EUR
76%
-370%
-392%
US
Gilead Sciences Inc
NASDAQ:GILD
103.2B USD
77%
37%
4%
AU
CSL Ltd
ASX:CSL
143.4B AUD
52%
26%
18%
US
Seagen Inc
F:SGT
39.3B EUR
75%
-33%
-33%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
34.6B USD
87%
4%
-3%
NL
argenx SE
NASDAQ:ARGX
32.4B USD
89%
-22%
-14%
Country US
Market Cap 40.1B USD
Gross Margin
97%
Operating Margin
-555%
Net Margin
-557%
Country US
Market Cap 344.8B USD
Gross Margin
67%
Operating Margin
29%
Net Margin
10%
Country US
Market Cap 180B USD
Gross Margin
63%
Operating Margin
20%
Net Margin
10%
Country US
Market Cap 128.6B USD
Gross Margin
87%
Operating Margin
31%
Net Margin
32%
Country US
Market Cap 126B USD
Gross Margin
86%
Operating Margin
41%
Net Margin
-5%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Operating Margin
-370%
Net Margin
-392%
Country US
Market Cap 103.2B USD
Gross Margin
77%
Operating Margin
37%
Net Margin
4%
Country AU
Market Cap 143.4B AUD
Gross Margin
52%
Operating Margin
26%
Net Margin
18%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Operating Margin
-33%
Net Margin
-33%
Country US
Market Cap 34.6B USD
Gross Margin
87%
Operating Margin
4%
Net Margin
-3%
Country NL
Market Cap 32.4B USD
Gross Margin
89%
Operating Margin
-22%
Net Margin
-14%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
Palatin Technologies Inc Competitors

Country Company Market Cap ROE ROA ROCE ROIC
US
Palatin Technologies Inc
LSE:0KF3
40.1B USD
-588%
-178%
-395%
-5 705%
US
Abbvie Inc
NYSE:ABBV
344.8B USD
54%
4%
16%
12%
US
Amgen Inc
NASDAQ:AMGN
180B USD
49%
3%
9%
8%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
128.6B USD
17%
13%
14%
17%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
126B USD
-3%
-2%
25%
-84%
US
Epizyme Inc
F:EPE
94.1B EUR
-877%
-67%
-73%
-182%
US
Gilead Sciences Inc
NASDAQ:GILD
103.2B USD
5%
2%
23%
13%
AU
CSL Ltd
ASX:CSL
143.4B AUD
16%
7%
12%
9%
US
Seagen Inc
F:SGT
39.3B EUR
-28%
-21%
-27%
-39%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
34.6B USD
35%
-2%
4%
9%
NL
argenx SE
NASDAQ:ARGX
32.4B USD
-8%
-7%
-12%
-31%
Country US
Market Cap 40.1B USD
ROE
-588%
ROA
-178%
ROCE
-395%
ROIC
-5 705%
Country US
Market Cap 344.8B USD
ROE
54%
ROA
4%
ROCE
16%
ROIC
12%
Country US
Market Cap 180B USD
ROE
49%
ROA
3%
ROCE
9%
ROIC
8%
Country US
Market Cap 128.6B USD
ROE
17%
ROA
13%
ROCE
14%
ROIC
17%
Country US
Market Cap 126B USD
ROE
-3%
ROA
-2%
ROCE
25%
ROIC
-84%
Country US
Market Cap 94.1B EUR
ROE
-877%
ROA
-67%
ROCE
-73%
ROIC
-182%
Country US
Market Cap 103.2B USD
ROE
5%
ROA
2%
ROCE
23%
ROIC
13%
Country AU
Market Cap 143.4B AUD
ROE
16%
ROA
7%
ROCE
12%
ROIC
9%
Country US
Market Cap 39.3B EUR
ROE
-28%
ROA
-21%
ROCE
-27%
ROIC
-39%
Country US
Market Cap 34.6B USD
ROE
35%
ROA
-2%
ROCE
4%
ROIC
9%
Country NL
Market Cap 32.4B USD
ROE
-8%
ROA
-7%
ROCE
-12%
ROIC
-31%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More
Back to Top